Baird upgraded Fortrea (FTRE) to Outperform from Neutral with a price target of $9, up from $7. The firm says the upgrade is not about the Q2 report the company’s 2025, but rather its long-term “compounding opportunity.” Baird cites negative sentiment in the shares and the group as well as a long-term view for the upgrade.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FTRE:
- FTRE Lawsuit Alert! Class Action Lawsuit Against Fortrea Holdings
- Fortrea price target lowered to $7 from $8 at Mizuho
- Fortrea announces strategic collaboration with Emery Pharma
- Oracle reports Q4 beat, BioNTech to acquire CureVac: Morning Buzz
- Fortrea Holdings Approves Key Proposals at Annual Meeting